MSI-H Detection via Random Forest Classifier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying microsatellite instability high (MSI-H) tumors using next-generation sequencing (NGS) data face challenges due to PCR and sequencing errors, which can lead to false classification of MS-Stable samples as MSI-H.
Innovation Solution
A computational method using a machine learning classifier algorithm is developed to classify tissue samples as MSI-H without requiring normal tissue from the same person. The method involves training the algorithm using known MSI-H and MS-Stable samples, determining the baseline distribution of repeats in microsatellite regions, and applying this to classify new samples based on their probability scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR and sequencing processes are used to amplify and analyze DNA samples, then DNA replication errors can be detected to identify MSI-H tumors, but PCR errors and sequencing errors are introduced that can cause false classification of MS-Stable samples as MSI-H
Solution Approach 1:
A machine learning classifier algorithm is introduced as an intermediary between the raw sequencing data and the final MSI-H classification. The algorithm processes NGS data, accounts for PCR and sequencing errors through training on known samples, and produces reliable classification results that distinguish true MSI-H tumors from MS-Stable samples without requiring normal tissue from the same person.
Solution Approach 2:
The machine learning classifier is trained using known MSI-H and MS-Stable samples to learn the baseline distribution of repeats in microsatellite regions. This training process creates a feedback mechanism where the algorithm continuously refines its ability to distinguish between true replication errors and artifacts, improving classification reliability over time.
2Measurement precision
If traditional MSI-H detection methods are used, then classification can be performed, but additional normal tissue sequencing is required which increases sequencing costs and sample preparation complexity
Solution Approach 1:
The method extracts and utilizes only the tumor tissue sample for analysis, eliminating the need for matched normal tissue from the same person. The machine learning classifier processes tumor DNA sequences directly, comparing microsatellite repeat distributions against learned baselines to determine MSI status, thereby reducing sample preparation complexity and sequencing costs.
Solution Approach 2:
Instead of requiring physical normal tissue samples, the method creates a computational copy or representation of the normal baseline through machine learning training on known MS-Stable samples. This virtual baseline allows the system to compare tumor samples against expected normal patterns without requiring actual normal tissue sequencing.
3Measurement precision
If a machine learning classifier algorithm is trained and applied to classify samples, then classification accuracy is improved, but computational resources and processing time are required
Solution Approach 1:
The machine learning classifier algorithm is pre-trained using known MSI-H and MS-Stable samples before actual classification is needed. This preliminary training action establishes the baseline distribution models and error correction parameters in advance, allowing rapid and accurate classification of new tumor samples without requiring time-consuming computational analysis during the diagnostic process.
Data Source
AI summary
A method is proposed where the distribution of repeats relative to the negative control sample in each run are calculated for each MSI loci. This distribution along with the average, are used as features to train a random forest classifier to identify MSI-H samples from other samples which are either MSS or MSI-L samples, collectively referred to as MS-Stable. In particular, the method distinguishes samples subject to artificial replication errors, such as PCR errors and sequencing errors. The resulting output that is produced is the probability of the sample being MSI-H, which is the MSI score of the sample. When samples are classified as MSI-HI, the finding is reported as indicative of sensitivity to immune modulation-checkpoint inhibitor treatment.